AI-Powered Precision Medicine

Drugging the Undruggable

Learn More

ProxAI is a techbio company specializing in the development of first-in-class protein therapeutics by leveraging artificial intelligence to address hard-to-drug disease targets. Our integrated solution features a high-throughput cell-based screening assay that rapidly evaluate thousands of AI-designed protein binder sequences in a single, one-shot assay.

See Our Platform

Our Unique
AI-Biology Platform

Discover how ProxAI leverages AI-driven protein design and cellular screening to accelerate protein therapeutic development with precision and efficiency.

Step 1: AI-Driven Design of Binders

We initiate by applying advanced AI algorithms to design highly specific protein binders tailored to disease triggering targets.

Step 2: High-Throughput Screening

Protein binders undergo rapid screening in physiologically relevant cellular environments to validate their binding and efficacy.

Step 3: Optimized Binder Selection

Finally, the most promising protein binder candidates are selected, streamlining progression toward clinical development.

Learn More

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by